S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
MRK · Merck & Co., Inc.
NEW YORK STOCK EXCHANGE, INC. - Real Time Price • USD
Merck & Co Inc (MRK)
NEW YORK STOCK EXCHANGE, INC.
Pharmaceuticals
$149.88
+1.64
(+1.11%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$149.88
$147.29
$149.99
52-WEEK RANGE
$149.88
$82.01
$156.92
What's happening
- MRK is up 1.11% today, trading at $149.88. — Live quote
- Volume today (473,777) is well below its 3-month average of 10,299,570. (Finnhub fundamentals)
- Reports earnings on 2026-10-29, 8 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.13 actual vs. $-0.27 estimated (+52.3%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 8
Buy 18
Hold 9
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (35 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
MRK
+36.45%
vs S&P 500
+24.05%
1-YEAR RETURN
MRK
+69.39%
vs S&P 500
+54.03%
6-MONTH RETURN
MRK
+21.82%
3-MONTH RETURN
MRK
+15.46%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.13
Est. $-0.27
BEAT +52.3%
2026-04-26 (Q1 2026)
$-1.28
Est. $-1.52
BEAT +16.0%
2026-01-26 (Q4 2025)
$2.09
Est. $2.03
BEAT +3.0%
2025-10-26 (Q3 2025)
$2.68
Est. $2.37
BEAT +13.1%
Valuation Measures & Ratios
Enterprise Value4$415.16B
Forward P/E519.63
PEG Ratio617.81
Price / Sales (TTM1)5.53
Price / Book77.57
EV4 / Revenue6.24
EV4 / EBITDA43.32
Profit Margin4.77%
Operating Margin9.58%
Return on Equity (ROE8)6.60%
Return on Assets (ROA9)2.42%
Avg Volume (3M)10,299,570
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $315.63B | $292.54B | $203.35B | $191.42B | $216.02B |
| P/E | 68.07 | 26.47 | 11.02 | 10.57 | 11.71 |
| Price/Sales | 4.78 | 4.51 | 3.12 | 2.99 | 3.37 |
| Price/Book | 7.53 | 6.38 | 3.92 | 3.91 | 4.47 |
| EV/Revenue | 5.45 | 5.14 | 3.45 | 3.39 | 3.76 |
| ROE | 11.06% | 24.09% | 35.58% | 36.98% | 38.18% |
| ROA | 3.57% | 8.59% | 14.24% | 15.42% | 16.03% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short28,271,750
Change from Prior Settlement-17.89%
% of Float—
Days to Cover (Short Ratio)2.53
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 5.1% on the provider's reported measure. Finnhub fundamentals ↗
- Trailing 52-week price return is +69.4%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is 4.8%. Finnhub fundamentals ↗
- Trailing P/E is 116.0, a high price relative to reported earnings. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-10-13; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on MRK
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $16.61B | $16.29B | $17.28B | $15.81B | $15.53B | $16.66B | $16.11B | $15.78B |
| Net income | -$1.33B | -$4.24B | $5.79B | $4.43B | $5.08B | $3.16B | $5.46B | $4.76B |
| EPS (diluted) | $-0.54 | $-1.72 | $2.32 | $1.76 | $2.01 | $1.24 | $2.14 | $1.87 |
| EPS (basic) | $-0.54 | $-1.72 | $2.32 | $1.76 | $2.01 | $1.25 | $2.15 | $1.88 |
| Net margin | -$8 | -$26 | $33 | $28 | $33 | $19 | $34 | $30 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $129.80B | $128.69B | $136.87B | $129.55B | $117.52B | $115.12B | $117.11B | $117.53B |
| Stockholders' equity | $41.93B | $45.88B | $52.61B | $51.85B | $48.99B | $48.34B | $46.31B | $44.50B |
| Total current assets | $36.68B | $35.02B | $43.52B | $47.56B | $37.06B | $35.50B | $38.78B | $40.36B |
| Total current liabilities | $27.73B | $26.95B | $28.33B | $28.63B | $26.04B | $25.17B | $28.42B | $29.59B |
| Cash & equivalents | $6.85B | $5.33B | $14.56B | $18.17B | $8.01B | $8.63B | $13.24B | $14.59B |
| Marketable securities (current) | $292.0M | $375.0M | $0 | $45.0M | $615.0M | $599.0M | $447.0M | $0 |
| Accounts receivable | $12.56B | $12.21B | $11.78B | $12.12B | $11.85B | $10.79B | $10.28B | $11.38B |
| Inventory | $6.21B | $6.48B | $6.66B | $6.44B | $6.60B | $6.20B | $6.11B | $6.24B |
| Other current assets | $10.77B | $10.62B | $10.52B | $10.78B | $10.00B | $9.29B | $8.71B | $8.14B |
| Marketable securities (non-current) | $1.22B | $1.10B | $956.0M | $1.12B | $774.0M | $616.0M | $463.0M | $575.0M |
| Property, plant & equipment | $25.74B | $25.43B | $25.32B | $25.64B | $25.24B | $24.79B | $23.78B | $23.45B |
| Goodwill | $21.58B | $21.58B | $21.58B | $21.59B | $21.59B | $21.68B | $21.67B | $21.70B |
| Intangible assets | $24.98B | $25.75B | $26.68B | $15.31B | $15.19B | $15.76B | $16.37B | $17.01B |
| Other non-current assets | $19.60B | $19.81B | $18.82B | $18.33B | $17.66B | $16.77B | $16.04B | $14.44B |
| Accounts payable | $3.83B | $3.86B | $4.40B | $4.15B | $3.89B | $3.78B | $4.08B | $3.59B |
| Short-term debt | — | — | $2.30B | — | — | — | $2.50B | — |
| Other current liabilities | $14.72B | $14.55B | $14.47B | $16.19B | $14.50B | $12.77B | $15.69B | $16.54B |
| Long-term debt | $51.08B | $46.67B | $46.75B | $39.97B | $33.97B | $33.48B | $34.46B | $34.98B |
| Other non-current liabilities | $7.57B | $7.64B | $7.69B | $7.66B | $7.03B | $6.66B | $6.46B | $7.54B |
| Common stock & paid-in capital | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B |
| Retained earnings | $63.27B | $66.72B | $73.08B | $72.23B | $68.48B | $66.10B | $63.07B | $61.38B |
| Accumulated other comprehensive income (loss) | -$3.94B | -$4.06B | -$4.29B | -$5.20B | -$5.42B | -$4.96B | -$4.95B | -$5.37B |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $5.37B | $3.92B | $2.86B | $7.82B | $3.29B | $2.50B | $3.45B | $9.29B |
| Investing cash flow | -$5.60B | -$10.21B | -$11.20B | -$283.0M | -$770.0M | -$1.49B | -$1.44B | -$3.85B |
| Financing cash flow | $1.76B | -$2.98B | $4.75B | $2.64B | -$3.56B | -$5.75B | -$3.01B | -$2.42B |
| Free cash flow | $4.48B | $2.93B | $1.82B | $6.83B | $2.53B | $1.17B | $2.51B | $8.51B |
| Capital expenditures | $893.0M | $991.0M | $1.03B | $987.0M | $764.0M | $1.33B | $937.0M | $783.0M |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $298.0M | $185.0M | $205.0M | $204.0M | $216.0M | $195.0M | $187.0M | $195.0M |
| Deferred income taxes | -$544.0M | -$315.0M | -$825.0M | -$212.0M | -$448.0M | -$186.0M | -$616.0M | -$401.0M |
| Change in accounts receivable | — | — | $1.09B | — | — | — | $244.0M | — |
| Change in inventory | — | — | $1.18B | — | — | — | $835.0M | — |
| Purchases of investments | $148.0M | $374.0M | $0 | $0 | $612.0M | $595.0M | $455.0M | $0 |
| Other investing activities | $22.0M | $66.0M | $172.0M | -$129.0M | -$5.0M | $20.0M | $57.0M | -$233.0M |
| Share repurchases | $757.0M | $874.0M | $1.25B | $1.32B | $1.34B | $1.16B | $489.0M | $444.0M |
| Debt issued | — | — | — | — | — | — | — | — |
| Debt repaid | $5.0M | $1.14B | $2.0M | $1.0M | $0 | $2.50B | $539.0M | $0 |
| Other financing activities | -$270.0M | -$80.0M | $121.0M | -$46.0M | -$146.0M | -$60.0M | -$42.0M | -$32.0M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $65.01B | $64.17B | $60.12B | $59.28B | $48.70B |
| Net income | $18.25B | $17.12B | $365.0M | $14.52B | $13.05B |
| EPS (diluted) | $7.28 | $6.74 | $0.14 | $5.71 | $5.14 |
| EPS (basic) | $7.30 | $6.76 | $0.14 | $5.73 | $5.16 |
| Net margin | $28 | $27 | $1 | $24 | $27 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $136.87B | $117.11B | $106.67B | $109.16B | $105.69B |
| Stockholders' equity | $52.61B | $46.31B | $37.58B | $45.99B | $38.18B |
| Total current assets | $43.52B | $38.78B | $32.17B | $35.72B | $30.27B |
| Total current liabilities | $28.33B | $28.42B | $25.69B | $24.24B | $23.87B |
| Cash & equivalents | $14.56B | $13.24B | $6.84B | $12.69B | $8.10B |
| Marketable securities (current) | $0 | $447.0M | $252.0M | $498.0M | — |
| Accounts receivable | $11.78B | $10.28B | $10.35B | $9.45B | $9.23B |
| Inventory | $6.66B | $6.11B | $6.36B | $5.91B | $5.95B |
| Other current assets | $10.52B | $8.71B | $8.37B | $7.17B | $6.99B |
| Marketable securities (non-current) | $956.0M | $463.0M | $252.0M | $1.01B | $370.0M |
| Property, plant & equipment | $25.32B | $23.78B | $23.05B | $21.42B | $19.28B |
| Goodwill | $21.58B | $21.67B | $21.20B | $21.20B | $21.26B |
| Intangible assets | $26.68B | $16.37B | $18.01B | $20.27B | $22.93B |
| Other non-current assets | $18.82B | $16.04B | $12.00B | $9.53B | — |
| Accounts payable | $4.40B | $4.08B | $3.92B | $4.26B | $4.61B |
| Short-term debt | $2.30B | $2.50B | $1.30B | $1.70B | $2.30B |
| Other current liabilities | $14.47B | $15.69B | $15.77B | $14.16B | $13.86B |
| Long-term debt | $46.75B | $34.46B | $33.68B | $28.75B | $30.69B |
| Other non-current liabilities | $7.69B | $6.46B | $8.79B | $8.32B | $9.43B |
| Common stock & paid-in capital | $1.79B | $1.79B | $1.79B | $1.79B | $1.79B |
| Retained earnings | $73.08B | $63.07B | $53.90B | $61.08B | $53.70B |
| Accumulated other comprehensive income (loss) | -$4.29B | -$4.95B | -$5.16B | -$4.77B | -$4.43B |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | $16.47B | $21.47B | $13.01B | $19.09B | — |
| Investing cash flow | -$13.74B | -$7.73B | -$14.08B | -$4.96B | — |
| Financing cash flow | -$1.92B | -$7.03B | -$4.81B | -$9.12B | — |
| Free cash flow | $12.36B | $18.10B | $9.14B | $14.71B | — |
| Capital expenditures | $4.11B | $3.37B | $3.86B | $4.39B | $4.45B |
| Depreciation & amortization | — | — | — | — | — |
| Share-based compensation | $820.0M | $761.0M | $645.0M | $541.0M | $479.0M |
| Deferred income taxes | -$1.67B | -$1.25B | -$1.90B | -$1.57B | $187.0M |
| Change in accounts receivable | $1.09B | $244.0M | $1.15B | $644.0M | $2.03B |
| Change in inventory | $1.18B | $835.0M | $816.0M | $161.0M | $674.0M |
| Purchases of investments | $1.21B | $519.0M | $955.0M | $1.20B | $1.0M |
| Other investing activities | $58.0M | $127.0M | $36.0M | $89.0M | $91.0M |
| Share repurchases | $5.08B | $1.31B | $1.35B | $0 | $840.0M |
| Debt issued | — | — | $5.94B | $0 | $7.94B |
| Debt repaid | $2.50B | $1.29B | $1.75B | $2.25B | $2.32B |
| Other financing activities | -$131.0M | -$372.0M | -$328.0M | -$240.0M | -$286.0M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding MRK as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 31 filers
Held by These Filers55.4%
Shares Outstanding2,470,000,000
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| BlackRock, Inc. | 226,999,837 | $29.17B | 9.19% | +0.5% | 2026-08-07 |
| VANGUARD CAPITAL MANAGEMENT LLC | 161,323,174 | $20.73B | 6.53% | +0.2% | 2026-06-30 |
| State Street Corp | 120,413,256 | $15.57B | 4.88% | +0.9% | 2026-08-07 |
| WELLINGTON MANAGEMENT GROUP LLP | 86,249,283 | $11.08B | 3.49% | +2.3% | 2026-08-14 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 67,738,969 | $8.70B | 2.74% | +0.6% | 2026-06-30 |
| GEODE CAPITAL MANAGEMENT, LLC | 60,744,214 | $7.79B | 2.46% | +2.0% | 2026-08-12 |
| Sixth Street Partners Management Company, L.P. | 54,365,289 | $6.99B | 2.20% | +0.0% | 2026-08-13 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 54,365,289 | $6.99B | 2.20% | +9.2% | 2026-08-14 |
| Morgan Stanley | 48,641,158 | $6.25B | 1.97% | +2.1% | 2026-08-11 |
| FMR LLC | 45,440,355 | $5.84B | 1.84% | +2.1% | 2026-08-13 |
| Jpmorgan Chase & Co | 43,886,420 | $5.68B | 1.78% | -17.2% | 2026-08-12 |
| Fisher Asset Management, LLC | 38,516,263 | $4.95B | 1.56% | +45.7% | 2026-08-04 |
| NORGES BANK | 36,983,784 | $4.75B | 1.50% | +0.0% | 2026-08-12 |
| Bank Of America Corp /De/ | 30,535,208 | $3.92B | 1.24% | -0.8% | 2026-08-14 |
| Northern Trust Corp | 26,275,718 | $3.38B | 1.06% | -3.0% | 2026-08-12 |
| Goldman Sachs Group Inc | 22,075,139 | $2.84B | 0.89% | +9.6% | 2026-08-14 |
| Franklin Templeton Inc | 19,548,585 | $2.51B | 0.79% | +20.2% | 2026-08-04 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 19,547,171 | $2.51B | 0.79% | -4.3% | 2026-08-13 |
| Legal & General Group Plc | 18,873,343 | $2.43B | 0.76% | -3.4% | 2026-08-14 |
| Invesco Ltd. | 18,611,171 | $2.39B | 0.75% | -14.8% | 2026-08-13 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 18,518,796 | $2.4M | 0.75% | -19.6% | 2026-08-14 |
| Bank of New York Mellon Corp | 18,340,173 | $2.36B | 0.74% | -2.0% | 2026-08-06 |
| DIMENSIONAL FUND ADVISORS LP | 17,486,486 | $2.25B | 0.71% | +13.1% | 2026-08-11 |
| Ameriprise Financial Inc | 17,387,435 | $2.24B | 0.70% | +6.9% | 2026-08-14 |
| Capital International Investors | 15,386,689 | $1.98B | 0.62% | +1668.1% | 2026-08-07 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-08-05 to 2026-08-13
Recent transactions
- Insiders have net sold 228,238 shares over the last 182 days, across 0 purchases and 17 sales.
- Most recent: Guindo Chirfi (EVP, Access, Policy & Comms) — Open market sale of 10,000 shares on 2026-08-13.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)228,238 sh(17 txns)
Net Shares-228,238
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Guindo Chirfi | EVP, Access, Policy & Comms | Open market sale | 2026-08-13 | 10,000 |
| Zachary Jennifer | EVP, General Counsel | Option exercise | 2026-08-12 | 41,494 |
| DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | Open market sale | 2026-08-12 | 11,099 |
| Maraldo David R. | EVP & Pres. MMD | Option exercise | 2026-08-05 | 6,311 |
| Williams David Michael | EVP,Chief Info&Digital Officer | Option exercise | 2026-08-05 | 4,600 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-13 | Guindo Chirfi | EVP, Access, Policy & Comms | Open market sale | 10,000 | $135.00 |
| 2026-08-12 | Zachary Jennifer | EVP, General Counsel | Option exercise | 41,494 | $117.89 |
| 2026-08-12 | Zachary Jennifer | EVP, General Counsel | Option exercise | 13,433 | $84.71 |
| 2026-08-12 | Zachary Jennifer | EVP, General Counsel | Open market sale | 80,315 | $133.46 |
| 2026-08-12 | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | Open market sale | 11,099 | $131.61 |
| 2026-08-12 | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | Open market sale | 600 | $132.04 |
| 2026-08-11 | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | Open market sale | 7,410 | $131.33 |
| 2026-08-11 | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | Open market sale | 5,427 | $132.35 |
| 2026-08-10 | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | Open market sale | 20,784 | $130.43 |
| 2026-08-06 | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | Open market sale | 805 | $131.02 |
| 2026-08-06 | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | Open market sale | 4,945 | $130.23 |
| 2026-08-06 | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | Open market sale | 300 | $131.02 |
| 2026-08-06 | Guindo Chirfi | EVP, Access, Policy & Comms | Open market sale | 15,000 | $131.00 |
| 2026-08-05 | Maraldo David R. | EVP & Pres. MMD | Option exercise | 6,311 | $73.73 |
| 2026-08-05 | Maraldo David R. | EVP & Pres. MMD | Open market sale | 6,311 | $128.72 |
| 2026-08-05 | Maraldo David R. | EVP & Pres. MMD | Option exercise | 9,709 | $87.10 |
| 2026-08-05 | Maraldo David R. | EVP & Pres. MMD | Open market sale | 9,709 | $128.72 |
| 2026-08-05 | Maraldo David R. | EVP & Pres. MMD | Option exercise | 2,686 | $84.71 |
| 2026-08-05 | Maraldo David R. | EVP & Pres. MMD | Open market sale | 2,686 | $128.72 |
| 2026-08-05 | Williams David Michael | EVP,Chief Info&Digital Officer | Option exercise | 4,600 | $77.62 |
| 2026-08-05 | Williams David Michael | EVP,Chief Info&Digital Officer | Open market sale | 4,600 | $128.77 |
| 2026-08-05 | Williams David Michael | EVP,Chief Info&Digital Officer | Option exercise | 13,542 | $75.36 |
| 2026-08-05 | Williams David Michael | EVP,Chief Info&Digital Officer | Open market sale | 13,542 | $128.77 |
| 2026-08-05 | Williams David Michael | EVP,Chief Info&Digital Officer | Option exercise | 34,705 | $73.73 |
| 2026-08-05 | Williams David Michael | EVP,Chief Info&Digital Officer | Open market sale | 34,705 | $128.77 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:14 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-13 | 8-K | 2026-10-09 | View on SEC.gov → |
| 2026-10-01 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-10-01 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-10-01 | 4 | 2026-09-30 | View on SEC.gov → |
| 2026-08-13 | 4 | 2026-08-13 | View on SEC.gov → |
| 2026-08-13 | 4 | 2026-08-12 | View on SEC.gov → |
| 2026-08-12 | 4 | 2026-08-10 | View on SEC.gov → |
| 2026-08-10 | 4 | 2026-08-06 | View on SEC.gov → |
| 2026-08-07 | 4 | 2026-08-05 | View on SEC.gov → |
| 2026-08-07 | 4 | 2026-08-05 | View on SEC.gov → |
| 2026-08-07 | 4 | 2026-08-06 | View on SEC.gov → |
| 2026-08-07 | 10-Q | 2026-06-30 | View on SEC.gov → |
Recent news
Headlines about MRK (Merck & Co., Inc.). Links open the publisher — we don’t host full articles.
-
Are You Overpaying For Regeneron Stock Versus Its Rivals?
Yahoo Finance · 2026-10-21 -
Merck (MRK) Laps the Stock Market: Here's Why
Yahoo Finance · 2026-10-21 -
Is One Older Drug The Biggest Risk To Bristol Myers Squibb Stock?
Yahoo Finance · 2026-10-21 -
MRK261016P00141000 Interactive Stock Chart | MRK Oct 2026 141.000 put Stock
Yahoo Finance · 2026-10-21 -
Keytruda, Padcev combo for bladder cancer approved by European Commission
Seeking Alpha · 2026-10-21 -
MRK Jan 2029 175.000 call (MRK290119C00175000) interactive stock chart
Yahoo Finance UK · 2026-10-21 -
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as Perioperative Treatment for Adults With Resectable Muscle-Invasive Bladder Cancer (MIBC)
Yahoo Finance · 2026-10-21 -
6,860 Merck & Co., Inc. $MRK Shares Sold by QV Investors Inc.
MarketBeat · 2026-10-21
No headlines in this category right now — try “All”.